DiaDexus, Inc. announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,052,862, covering methods of diagnosing a patient's susceptibility for developing an atherosclerotic disease, including myocardial infarction and stroke, by analyzing a sample of a patient's blood for the presence and activity of Lipoprotein Associated Phospholipase A2 (Lp-PLA2) enzymatic activity to determine a patient's susceptibility to developing atherosclerotic disease, including stroke and myocardial infarction. Lp-PLA2, an enzyme associated with atherosclerotic plaque, was discovered by scientists at GlaxoSmithKline (GSK). This patent is one of several GSK patents to which diaDexus has an exclusive commercial diagnostic license.
Yahoo News
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Inova Diagnostics’ Assay Cleared by FDA
Inova’s test can help identify patients who are at severe risk of illness and often need aggressive immunosuppressive therapy.
Indian Drugmaker Draws FDA Warning for Adulterated Products
The firm attributed out-of-specification and out-of-trend assay results for certain tablets to sampling preparation errors but didn’t provide any evidence to support the findings.
FDAnews Device Daily Bulletin
DIADEXUS ISSUED U.S. PATENT FOR LP-PLA2 ACTIVITY-BASED ATHEROSCLEROSIS DIAGNOSTIC TEST
May 31, 2006